A Path Forward for Families with Hereditary Cancer
Lynch syndrome is the most common cause of
hereditary cancers but difficult to diagnose.
Lynsight offers a new way to test for Lynch
syndrome, so healthcare providers can focus on
the path instead of the problem.
Lynch syndrome is the most common cause of hereditary cancers but difficult to diagnose. Lynsight offers a new way to test for Lynch syndrome, so healthcare providers can focus on the path instead of the problem.
1
in
279
People have Lynch syndrome
But only 35% of Lynch syndrome cases are confirmed through DNA sequencing, leaving patients, families, and providers in a state of uncertainty.
DiagMMR is Lynsight’s simple and accurate test that reliably detects mismatch repair (MMR) deficiency, supporting early Lynch syndrome diagnosis.
DiagMMR is Lynsight’s simple and accurate test that reliably detects mismatch repair (MMR) deficiency, supporting early Lynch syndrome diagnosis.
Lynch syndrome research
Predictive cancer diagnostics: LS CancerDiag Ltd has developed DiagMMR, an innovative method to detect cancer syndrome before cancers form.
Functional Analyses Help to Assess the Pathogenicity of MMR Gene Variants of Uncertain Significance
Mismatch repair defects in cancer
Mutations of a mutS Homolog in Hereditary Nonpolyposis Colorectal Cancer
DNA Mismatch Repair Gene Mutations in 55 Kindreds with Verified Or Putative Hereditary Non-Polyposis Colorectal Cancer
Lack of MSH2 and MSH6 Characterizes Endometrial but not Colon Carcinomas in Hereditary Nonpolyposis Colorectal Cancer
Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome
Two mismatch repair gene mutations found in a colon cancer patient – which one is pathogenic?
MSH6 missense mutations are often associated with no or low cancer susceptibility
Functional Significance and Clinical Phenotype of Nontruncating Mismatch Repair Variants of MLH1
Pathogenicity of MSH2 Missense Mutations Is Typically Associated With Impaired Repair Capability of the Mutated Protein
Mechanisms of pathogenicity in human MSH2 missense mutants
Founded by the leaders
in Lynch syndrome research
Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. What started in the labs of the University of Helsinki in the 1990s will not stop until every potential Lynch syndrome case is tested